An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
1 Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
2 IRCCS Neuromed, Pozzilli, Italy.
3 Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
4 Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada.
5 Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
6 Krembil Brain Institute, Toronto, Ontario, Canada.
7 Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
1 Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
2 IRCCS Neuromed, Pozzilli, Italy.
3 Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
4 Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada.
5 Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
6 Krembil Brain Institute, Toronto, Ontario, Canada.
7 Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
None of the authors have any potential conflicts of interest to disclose.
Relevant conflicts of interest/financial disclosures: Nothing to report.
Figures
FIG. 1.
The figure schematically represents the…
FIG. 1.
The figure schematically represents the two main dimensions of voluntary movement, namely velocity…
FIG. 1.
The figure schematically represents the two main dimensions of voluntary movement, namely velocity (x-axis) and amplitude (y-axis). Based on these two values, the movement can be considered predominantly bradykinetic if of reduced velocity or hypokinetic if of reduced amplitude. If both parameters are markedly reduced, the movement is defined as akinetic. Conversely, amplitude and velocity may be within a normal range (eukinesia). In some cases, velocity and amplitude may have values that exceed normal limits, as observed in some hyperkinesias, for example, ballismus. The dashed area at the lower right indicates markedly reduced amplitude but high velocity movements. The dashed area at the upper left indicates markedly reduced velocity but high amplitude movements. Dotted and dashed areas overall indicate unlikely movement values. With the repetition of the movement (z-axis), changes in motor performance can be observed in terms of amplitude and/or velocity reduction (sequence effect) or motor hesitations/halts. Note that although in this figure distinct limits are depicted to differentiate the various areas, these limits may be blurred in the reality. Again, the limits for the definition of movement abnormalities are arbitrary and may be modified in future experimental studies, though the conceptual framework of the new definition of bradykinesia elaborated here should remain unchanged.
Wenning GK, Stankovic I, Vignatelli L, et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord 2022;37(6):1131–1148. 10.1002/mds.29005
-
DOI
-
PMC
-
PubMed
Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80(5):496–503. 10.1212/WNL.0b013e31827f0fd1
-
DOI
-
PMC
-
PubMed
Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 2013;20(1):16–34. 10.1111/ene.12022
-
DOI
-
PubMed
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015;30(12):1591–1601. 10.1002/mds.26424
-
DOI
-
PubMed
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 2017;32(6):853–864. 10.1002/mds.26987
-
DOI
-
PMC
-
PubMed